{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:08:11Z","timestamp":1760144891443,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Immune checkpoint blockade (ICB) has presented a breakthrough in the treatment of malignant tumors and increased the overall survival of patients with various tumor entities. ICB may also cause immune-related adverse events, such as pneumonitis or interstitial lung disease. The lung clearance index (LCI) is a multiple-breath washout technique offering information on lung pathology in addition to conventional spirometry. It measures the degree of pulmonary ventilation inhomogeneity and allows early detection of pulmonary damage, especially that to peripheral airways. Methods: This cross-sectional study compared the lung function of patients with melanoma or metastatic cutaneous squamous cell carcinoma who received programmed cell death 1 (PD-1) and cytotoxic T-Lymphocyte-associated Protein 4 (CTLA-4) antibodies, alone or in combination, to age- and sex-matched controls. Lung function was assessed using spirometry, according to American Thoracic Society and European Respiratory Society standards, the LCI, and a diffusion capacity of carbon monoxide (DLCO) measurement. Results: Sixty-one screened patients and thirty-eight screened controls led to nineteen successfully included pairs. The LCI in the ICB-treated patients was 8.41 \u00b1 1.15 (mean \u00b1 SD), which was 0.32 higher compared to 8.07 \u00b1 1.17 in the control group, but the difference was not significant (p = 0.452). The patients receiving their ICB therapy for under five months showed a significantly lower LCI (7.98 \u00b1 0.77) compared to the ICB patients undergoing therapy for over five months (9.63 \u00b1 1.22) at the point of testing (p = 0.014). Spirometric analysis revealed that the forced expiratory volume between 25 and 75% of the forced vital capacity (FEF25\u201375%) in the ICB-treated patients was significantly reduced (p = 0.047) compared to the control group. DLCO (%predicted and adjusted for hemoglobin) was 94.4 \u00b1 19.7 in the ICB patients and 93.4 \u00b1 21.7 in the control group (p = 0.734). Conclusions: The patients undergoing ICB therapy showed slightly impaired lung function compared to the controls. Longer periods of ICB treatment led to deterioration of the LCI, which may be a sign of a subclinical inflammatory process. The LCI is feasible and may be easily integrated into the clinical daily routine and could contribute to early detection of pulmonary (auto-)inflammation.<\/jats:p>","DOI":"10.3390\/cancers16112088","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T03:46:49Z","timestamp":1717127209000},"page":"2088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lung Clearance Index as a Screening Parameter of Pulmonary Impairment in Patients under Immune Checkpoint Therapy: A Pilot Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Maya-Leonie C.","family":"Steinbach","sequence":"first","affiliation":[{"name":"Children\u2019s and Adolescent Clinic, Department of Pneumology and Allergology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2821-1666","authenticated-orcid":false,"given":"Jakob","family":"Eska","sequence":"additional","affiliation":[{"name":"Clinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Weitzel","sequence":"additional","affiliation":[{"name":"Children\u2019s and Adolescent Clinic, Department of Pneumology and Allergology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra R.","family":"G\u00f6rges","sequence":"additional","affiliation":[{"name":"Children\u2019s and Adolescent Clinic, Department of Pneumology and Allergology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Tietze","sequence":"additional","affiliation":[{"name":"Clinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Ballmann","sequence":"additional","affiliation":[{"name":"Children\u2019s and Adolescent Clinic, Department of Pneumology and Allergology, University Medical Center Rostock, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma","volume":"23","author":"Barone","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00120-018-0635-1","article-title":"Therapie mit PD-1\/PD-L1-und CTLA-4-Immun-Checkpoint-Inhibitoren","volume":"57","author":"Grimm","year":"2018","journal-title":"Urologe"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated with Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor\u2013Related Pneumonitis in Patients with Advanced Cancer: A Systematic Review and Meta-Analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Disayabutr, S., Calfee, C.S., Collard, H.R., and Wolters, P.J. (2015). Interstitial lung diseases in the hospitalized patient. BMC Med., 13.","DOI":"10.1186\/s12916-015-0487-0"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/14740338.2015.1021774","article-title":"Safety of pembrolizumab for the treatment of melanoma","volume":"14","author":"Kordbacheh","year":"2015","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e000840","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: Focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00262-017-2071-2","article-title":"Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: A prospective observational study","volume":"67","author":"Franzen","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_18","first-page":"P3797","article-title":"Tidal N2 washout ventilation inhomogeneity indices in a reference population aged 7\u201370 years","volume":"40","author":"Houltz","year":"2012","journal-title":"Eur. Respir. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1183\/20734735.012717","article-title":"The Global Lung Function Initiative (GLI) Network: Bringing the world\u2019s respiratory reference values together","volume":"13","author":"Cooper","year":"2017","journal-title":"Breathe"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-15-59","article-title":"Lung clearance index in adults with non-cystic fibrosis bronchiectasis","volume":"15","author":"Gonem","year":"2014","journal-title":"Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.05.00034505","article-title":"General considerations for lung function testing","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1183\/09031936.05.00035005","article-title":"Standardisation of the measurement of lung volumes","volume":"26","author":"Wanger","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1183\/09031936.05.00034905","article-title":"Standardisation of the single-breath determination of carbon monoxide uptake in the lung","volume":"26","author":"MacIntyre","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-year age range: The global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.2147\/COPD.S261732","article-title":"FEF25\u201375% Values in Patients with Normal Lung Function Can Predict the Development of Chronic Obstructive Pulmonary Disease","volume":"15","author":"Kwon","year":"2020","journal-title":"Int. J. Chron. Obs. Pulmon. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1183\/09031936.00128113","article-title":"Measurement of FEF25\u201375% and FEF75% does not contribute to clinical decision making","volume":"43","author":"Quanjer","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1378\/chest.84.4.473","article-title":"Spirometry: FEV, vs. FEF25\u201375 Percent","volume":"84","author":"Gelb","year":"1983","journal-title":"Chest"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/thx.2007.082628","article-title":"Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis","volume":"63","author":"Horsley","year":"2008","journal-title":"Thorax"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/thx.2006.068262","article-title":"Early detection of cystic fibrosis lung disease: Multiple-breath washout versus raised volume tests","volume":"62","author":"Lum","year":"2007","journal-title":"Thorax"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201610-2158OC","article-title":"Progression of Lung Disease in Preschool Patients with Cystic Fibrosis","volume":"195","author":"Stanojevic","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1164\/rccm.200407-895OC","article-title":"Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis","volume":"171","author":"Aurora","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","first-page":"w14483","article-title":"Inert gas washout: Background and application in various lung diseases","volume":"147","author":"Usemann","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ppul.24360","article-title":"Lung function in children with juvenile idiopathic arthritis: A cross-sectional analysis","volume":"54","author":"Attanasi","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.03.00049502","article-title":"Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis","volume":"22","author":"Gustafsson","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_39","first-page":"170","article-title":"Lung Clearance Index (LCI) and diffusion capacity of the lung (DLCO) in children with rheumatic disease","volume":"56","author":"Hildebrandt","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prrv.2011.05.001","article-title":"Lung clearance index: Clinical and research applications in children","volume":"12","author":"Fuchs","year":"2011","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/ppul.25071","article-title":"Lung clearance index: A new measure of late lung complications of cancer therapy in children","volume":"55","author":"Parisi","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:26Z","timestamp":1760107886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16112088"],"URL":"https:\/\/doi.org\/10.3390\/cancers16112088","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}